Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness
NCT00661869 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 295
Last updated 2010-08-09
Summary
Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.
Conditions
- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
Interventions
- OTHER
-
Wellness Program
36 weeks of educational and supportive interventions
Sponsors & Collaborators
- collaborator INDUSTRY
-
Manhattan Psychiatric Center
lead OTHER
Principal Investigators
-
Jean-Pierre Lindenmayer, M.D. · New York University School of Medicine & Manhattan Psychaitric Center
Study Design
- Allocation
- NA
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-09-30
- Primary Completion
- 2007-09-30
- Completion
- 2008-01-31
Countries
- United States
Study Locations
More Related Trials
-
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
NCT00345033 ·Status: COMPLETED ·Phase: PHASE4
-
Short Term Rescue Study of Olanzapine
NCT00186017 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of a Weight Management Program During Treatment With Olanzapine
NCT00169702 ·Status: COMPLETED ·Phase: NA
-
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00176436 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00090012 ·Status: COMPLETED ·Phase: PHASE4
-
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
NCT00303602 ·Status: COMPLETED ·Phase: PHASE4
-
Naltrexone for Antipsychotic-Induced Weight Gain
NCT01866098 ·Status: COMPLETED ·Phase: NA
-
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
NCT00363376 ·Status: COMPLETED ·Phase: PHASE3
-
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
NCT05542264 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
NCT00485823 ·Status: COMPLETED ·Phase: PHASE4
-
Weight Gain Management in Patients With Schizophrenia
NCT00486005 ·Status: COMPLETED ·Phase: PHASE4
-
The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044187 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00100776 ·Status: COMPLETED ·Phase: PHASE4
-
A Placebo-Controlled, Cross-Over Trial of Aripiprazole
NCT00351936 ·Status: COMPLETED ·Phase: PHASE4
-
A Study for Patients With Schizophrenia
NCT00520923 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder
NCT00179062 ·Status: COMPLETED ·Phase: NA
-
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
NCT00113594 ·Status: COMPLETED ·Phase: PHASE3
-
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00103571 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
NCT04709224 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in Schizophrenia
NCT01355952 ·Status: COMPLETED ·Phase: NA
-
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCT00734435 ·Status: TERMINATED ·Phase: PHASE2
-
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
NCT00690235 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
NCT00510211 ·Status: COMPLETED
-
Olanzapine in the Treatment of Patients With Anorexia Nervosa
NCT00260962 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
NCT00423878 ·Status: COMPLETED ·Phase: PHASE4